BioPharma APAC - Leading Source of Biopharmaceutical Intelligence in Asia Pacific

China

OBiO and CHINAGENE to provide gene therapy commercial manufacturing services under strategic agreement.

"This agreement signed by OBiO and CHINAGENE is a continuation and sublimation from previous cooperation," Guodong Jia, CEO of OBiO said, "CHINAGENE i...

April 30, 2023 | News

Cartherics grants Shunxi Licence for CAR-T Cell Therapy for Ovarian Cancer in Greater China

CTH-004 has shown promising results in animal models of ovarian cancer and will be evaluated in a clinical trial under a research and development...

April 28, 2023 | News

RNAimmune's RV-1730 COVID-19 booster vaccine receives FDA clearance for Phase 1 trial.

The proposed clinical study will involve in an evaluation of RV-1730 for its safety and prophylaxis efficacy against SARS-CoV-2 infection with people...

April 28, 2023 | News

Fapon Biotech Announces Chemiluminescence One-Stop Solution Strategy in India at Medical Fair India 2023

Fapon chemiluminescence one-stop solution is designed to provide a complete range of chemiluminescence products and services, consisting of different level...

April 27, 2023 | News

Gracell Biotech to Unveil BCMA/CD19 FasTCAR-T GC012F Clinical Data at 2023 ASCO Meet

"We are looking forward to sharing updated results from our ongoing studies evaluating GC012F in relapsed/refractory multiple myeloma and B-cell non-Hodgki...

April 27, 2023 | News

Fosun Pharma Develops Innovative Artemisinin-based Antimalarials for Malaria-free World via Belt and Road

This year 2023 also marks the 10th anniversary of the Belt and Road Initiative. Medicine knows no borders. Artemisinin and its derivatives have moved ...

April 27, 2023 | News

I-Mab Announces Positive Outcome in Arbitration Relating to Agreements with Tracon

Award is an important victory for I-Mab and its shareholders on multiple levels, ending the multi-year long dispute Tribunal completely denied Tracon's ...

April 26, 2023 | News

I-Mab Doses First Patient in Phase 3 Study of Lemzoparlimab for MDS in China

The Phase 3 trial is a randomized, controlled, open-label, multi-center study to evaluate the efficacy and safety of lemzoparlimab in combination with AZA ...

April 25, 2023 | News

OBiO Technology Launches New Super Factory in Shanghai with 29 GMP-Grade Production Lines for Gene and Cell Therapy

At the opening ceremony, OBiO showed the holistic process development capability and large-scale GMP manufacturing capacity in variety gene and cell therap...

April 25, 2023 | News

Ascentage Pharma Achieves EU GMP Compliance with Zero Deficiencies

Ascentage Pharma (6855.HK), a global biopharmaceutical company engaged in developing novel therapies for cancers, chronic hepatitis B (CHB), and age-...

April 25, 2023 | News

Everest Medicines Launches First-in-Disease Therapy for IgA Nephropathy in China's Hainan Boao Pilot Zone.

The launch of this early-access program in Hainan marks the beginning of a new treatment era for IgA nephropathy in China, where Everest can...

April 24, 2023 | News

CARsgen's CT041 receives IND clearance from NMPA for pancreatic cancer therapy.

Dr Raffaele Baffa, Chief Medical Officer of CARsgen, commented that "We are glad to receive the IND clearance from NMPA for the adjuvant treatment of ...

April 20, 2023 | News

Crystal Formulation Services Receives China Drug Manufacturing License for Milestone Formulation Capability

Crystal Formulation Services, a subsidiary of Crystal Pharmatech, has achieved an exciting new milestone in its formulation capabilities. The company was r...

April 20, 2023 | News

Biosyngen announces FDA IND approval of its second product for EBV-positive lymphoma

A few months earlier, the Company's first product (BRG01) targeting relapsed/metastatic nasopharyngeal cancer has been granted IND approval by both the US ...

April 19, 2023 | News

Stay Connected